Bicara Therapeutics (BCAX) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BCAX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bicara Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.25 |
| 52 Week High | US$28.09 |
| 52 Week Low | US$7.80 |
| Beta | 0 |
| 1 Month Change | 66.36% |
| 3 Month Change | 66.97% |
| 1 Year Change | -16.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.04% |
Recent News & Updates
Bicara Therapeutics: Promising, But Only For The Patient
Sep 04We're Not Very Worried About Bicara Therapeutics' (NASDAQ:BCAX) Cash Burn Rate
Jul 15
Recent updates
Bicara Therapeutics: Promising, But Only For The Patient
Sep 04We're Not Very Worried About Bicara Therapeutics' (NASDAQ:BCAX) Cash Burn Rate
Jul 15Bicara: Innovative Precision Tumor Targeting
Apr 19We Think Bicara Therapeutics (NASDAQ:BCAX) Can Afford To Drive Business Growth
Mar 13Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me
Feb 02Shareholder Returns
| BCAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.6% | 2.8% | 1.7% |
| 1Y | -16.9% | 0.1% | 14.5% |
Return vs Industry: BCAX underperformed the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: BCAX underperformed the US Market which returned 14.5% over the past year.
Price Volatility
| BCAX volatility | |
|---|---|
| BCAX Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BCAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BCAX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 55 | Claire Mazumdar Clemon | www.bicara.com |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc. Fundamentals Summary
| BCAX fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$102.67m |
| Revenue (TTM) | n/a |
Is BCAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCAX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$102.67m |
| Earnings | -US$102.67m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 16:50 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bicara Therapeutics Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Richard J. Law | Goldman Sachs |
| Robert Burns | H.C. Wainwright & Co. |